Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Thomas Powles¹, Mark Kockx², Alejo Rodriguez-Vida³, Ignacio Duran⁴, Simon J Crabb⁵, Michiel S Van Der Heijden⁶, Bernadett Szabados⁷, Albert Font Pous⁸, Gwenaelle Gravis⁹, Urbano Anido Herranz¹⁰, Andrew Protheroe¹¹, Alain Ravaud¹², Denis Maillet¹³, Maria Jose Mendez¹⁴, Cristina Suarez¹⁵, Mark Linch¹⁶, Aaron Prendergast⁷, Pieter-Jan van Dam², Diana Stanoeva², Sofie Daelemans^{2

17}, Sanjeev Mariathasan¹⁸, Joy S Tea¹⁸, Kelly Mousa⁷, Romain Banchereau^#¹⁸, Daniel Castellano^#¹⁹

Affiliations

¹ Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. t.powles@qmul.ac.uk.
² HistogeneX N.V., Wilrijk, Belgium.
³ Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
⁴ Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain.
⁵ Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.
⁶ Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁷ Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
⁸ Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
⁹ Institut Paoli-Calmettes, Marseille, France.
¹⁰ Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain.
¹¹ Department of Medical Oncology, Churchill Hospital, Oxford, UK.
¹² Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux-CHU Bordeaux, Bordeaux, France.
¹³ Department of Medical Oncology, Hospital Lyon Sud, Lyon, France.
¹⁴ Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain.
¹⁵ Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
¹⁶ Department of Medical Oncology, University College London Hospital, London, UK.
¹⁷ Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium.
¹⁸ Genentech, San Francisco, CA, USA.
¹⁹ Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain.

^# Contributed equally.

PMID: 32555515
DOI: 10.1038/s41591-020-0923-3

Published Erratum

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Thomas Powles et al. Nat Med. 2020 Jun.

. 2020 Jun;26(6):983.

doi: 10.1038/s41591-020-0923-3.

Authors

Affiliations

¹ Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. t.powles@qmul.ac.uk.
² HistogeneX N.V., Wilrijk, Belgium.
³ Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
⁴ Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain.
⁵ Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.
⁶ Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
⁷ Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
⁸ Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
⁹ Institut Paoli-Calmettes, Marseille, France.
¹⁰ Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain.
¹¹ Department of Medical Oncology, Churchill Hospital, Oxford, UK.
¹² Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux-CHU Bordeaux, Bordeaux, France.
¹³ Department of Medical Oncology, Hospital Lyon Sud, Lyon, France.
¹⁴ Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain.
¹⁵ Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
¹⁶ Department of Medical Oncology, University College London Hospital, London, UK.
¹⁷ Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium.
¹⁸ Genentech, San Francisco, CA, USA.
¹⁹ Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain.

^# Contributed equally.

PMID: 32555515
DOI: 10.1038/s41591-020-0923-3

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

PubMed Disclaimer

Erratum for

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Powles T, et al. Nat Med. 2019 Nov;25(11):1706-1714. doi: 10.1038/s41591-019-0628-7. Epub 2019 Nov 4. Nat Med. 2019. PMID: 31686036 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Affiliations

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Authors

Affiliations

Abstract

Erratum for

Publication types

LinkOut - more resources

Full Text Sources